Endpoints of therapy in chronic hepatitis B. (Q37462552)

20 August 2017

title

Endpoints of therapy in chronic hepatitis B. (English)

1 reference

20 August 2017

1 reference

Jordan J Feld

1 reference

20 August 2017

David K H Wong

series ordinal

1 reference

20 August 2017

E Jenny Heathcote

series ordinal

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

20 August 2017

1 reference

20 August 2017

1 reference

20 August 2017

issue

5 Suppl

1 reference

20 August 2017

page(s)

S96-S102

1 reference

Sampling variability of liver fibrosis in chronic hepatitis C.

20 August 2017

cites work

1 reference

Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model

21 January 2018

1 reference

Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study

21 January 2018

1 reference

7 January 2021

Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications

1 reference

7 January 2021

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

7 January 2021

Need to strictly define hepatitis B virus immunotolerant patients to avoid unnecessary liver biopsy

1 reference

7 January 2021

Hepatitis B e antigen and the risk of hepatocellular carcinoma

1 reference

7 January 2021

HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.

1 reference

7 January 2021

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

1 reference

7 January 2021

Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response

1 reference

7 January 2021

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

1 reference

7 January 2021

Virological and biochemical relapse after discontinuation of lamivudine monotherapy for chronic hepatitis B in Japan: comparison with breakthrough hepatitis during long-term treatment

1 reference

7 January 2021

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

1 reference

7 January 2021

Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B.

1 reference

7 January 2021

A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

1 reference

7 January 2021

Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study

1 reference

7 January 2021

Serum markers detect the presence of liver fibrosis: a cohort study

1 reference

7 January 2021

Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis

1 reference

7 January 2021

Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

1 reference

7 January 2021

Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study

1 reference

7 January 2021

Liver stiffness in the hepatitis B virus carrier: a non-invasive marker of liver disease influenced by the pattern of transaminases

1 reference

7 January 2021

Prevalence of fibrosis and cirrhosis in chronic hepatitis B: implications for treatment and management

1 reference

7 January 2021

Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years

1 reference

7 January 2021

HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up

1 reference

7 January 2021

Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.22977

1 reference

20 August 2017

1 reference